Bioniz Therapeutics Secures $13,000,000 Series A Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=b0bd0224-ecbd-41b9-817b-656a1b29e233 - Date
8/3/2016 - Company Name
Bioniz Therapeutics - Mailing Address
5 Mason St. Irvine, CA 92618 USA - Company Description
Bioniz is a biopharmaceutical company leading the discovery and development of first-in-class multi-cytokine inhibitory peptide therapeutics to address immuno-inflammatory diseases and cancer, with an initial focus on orphan diseases that have an immune component. - Website
http://www.bioniz.com - Transaction Type
Venture Equity - Transaction Amount
$13,000,000 - Transaction Round
Series A - Proceeds Purposes
The Series A funding will allow Bioniz to further advance its peptide platform technology focused on selective blockade of key cytokines that modulate serious diseases. - M&A Terms
- Venture Investor
Takeda Ventures - Venture Investor
Cota Capital - Venture Investor
Investor - Venture Investor
Investor
